Celldex Therapeutics (CLDX) Other Operating Expenses (2010 - 2023)
Celldex Therapeutics (CLDX) posted quarterly Other Operating Expenses of $12.5 million for Q4 2023, up 32794.74% year-over-year from N/an in Q4 2022, and up 32794.74% quarter-over-quarter from $38000.0 in Q4 2022.
Celldex Therapeutics (CLDX) Other Operating Expenses (2010 - 2023) Analysis & Trends
Celldex Therapeutics' Other Operating Expenses history runs 14 years deep, the most recent figure standing at $12.5 million for Q4 2023.
- In Q4 2023, Other Operating Expenses rose 32794.74% year-over-year to $12.5 million; the TTM figure through Sep 2024 stood at $12.5 million (up 32794.74% YoY), while the FY2023 annual figure was -$12.5 million, down 281.16% from the prior year.
- Other Operating Expenses for Q4 2023 stood at $12.5 million, up from $38000.0 in the prior quarter.
- The five-year high for Other Operating Expenses was $12.5 million in Q4 2023, with the low at -$1.5 million in Q1 2019.
- The 5-year median for Other Operating Expenses is $121500.0 (2021), against an average of $1.6 million.
- The sharpest annual moves came in 2020 and 2023: Other Operating Expenses tumbled 133.11% in 2020, then surged 32794.74% in 2023.
- Celldex Therapeutics' Other Operating Expenses stood at -$318000.0 in 2019, then jumped by 105.66% to $18000.0 in 2020, then jumped by 1038.89% to $205000.0 in 2021, then sank by 81.46% to $38000.0 in 2022, then soared by 32794.74% to $12.5 million in 2023.
- Business Quant data shows CLDX's Other Operating Expenses at $12.5 million in Q4 2023, $38000.0 in Q4 2022, and $6.3 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 12.50 Mn |
| Dec 31, 2022 | 38,000.00 |
| Jun 30, 2022 | 6.33 Mn |
| Mar 31, 2022 | 536,000.00 |
| Dec 31, 2021 | 205,000.00 |
| Sep 30, 2021 | 1.90 Mn |
| Jun 30, 2021 | -300,000.00 |
| Mar 31, 2021 | -483,000.00 |
| Dec 31, 2020 | 18,000.00 |
| Sep 30, 2020 | -700,000.00 |
| Jun 30, 2020 | 5.13 Mn |
| Mar 31, 2020 | -234,000.00 |
| Dec 31, 2019 | -318,000.00 |
| Sep 30, 2019 | 2.11 Mn |
| Jun 30, 2019 | 1.02 Mn |
| Mar 31, 2019 | -1.52 Mn |
| Dec 31, 2018 | 1.65 Mn |
| Sep 30, 2018 | 6.94 Mn |
| Jun 30, 2018 | 7.43 Mn |
| Mar 31, 2018 | 13.60 Mn |